@WHO: The licence for the #COVID19 serological antibody technology will be royalty-free for low- & middle-income countries & will remain valid until the date the last patent expires. @CSIC will provide all know-how to @MedsPatentPool &/or to prospective licensees as well as training. https://t.co/OZPtKhvZOO

http://twitter.com/WHO
via IFTTT